As Sanofi works to gain traction for the launch of its world-first dengue vaccine, a potential competitor may be building its case. This week, the National Institutes of Health announced that a candidate developed by scientists there posted "very encouraging" results, according to the team's lead scientist.
Sanofi's Dengvaxia is set for a wide rollout in the Philippines, making the endemic nation the first to implement an immunization campaign utilizing the dengue fever vaccine.
Sanofi is moving into 2016 with a head of steam for its Dengvaxia launch, with execs announcing on the company's year-end conference call that the French pharma has delivered its first million doses in the Philippines.
The high-stakes rollout of Sanofi's dengue vaccine, Dengvaxia, is slated this month in the private market, the lead executive for the product said, adding that a tender for 3 million doses is in advanced discussions in the Philippines for a public launch within weeks.
Sanofi Pasteur spent 20 years and $1.5 billion researching its dengue fever vaccine, Dengvaxia, and now it's looking to maximize the vaccine's impact. To do that, the French pharma's vaccine division is working with regulators and health officials to identify implementation strategies, program head Guillaume Leroy told FierceVaccines.
A waiver of large-scale clinical trials for Sanofi's dengue vaccine, Dengvaxia, was recommended by a special committee that advises the Drug Controller General of India, the Economic Times reports.
The Philippines' FDA approved Sanofi's first-of-its-kind dengue fever vaccine, Dengvaxia, on Tuesday. And on the same day, India's Economic Times reported that the government there is exploring opportunities to accelerate marketing authorization for the vaccine, considering exempting it from large local clinical trials.